54 related articles for article (PubMed ID: 25388751)
1. Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis.
Mabuchi T; Yamaoka H; Kawai M; Ota T; Ozawa A
J Dermatol; 2014 Dec; 41(12):1136-7. PubMed ID: 25388751
[No Abstract] [Full Text] [Related]
2. First experience with therapy of severe forms of psoriasis with biosimilar infliximab.
Tichy M; Kopova R; Sternbersky J
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):491-3. PubMed ID: 25418715
[No Abstract] [Full Text] [Related]
3. The International Psoriasis Council: advancing knowledge, enhancing care.
Alan Menter M; Griffiths CE
Dermatol Clin; 2015 Jan; 33(1):ix-xii. PubMed ID: 25412791
[No Abstract] [Full Text] [Related]
4. Psoriatic arthritis for the dermatologist.
Tintle SJ; Gottlieb AB
Dermatol Clin; 2015 Jan; 33(1):127-48. PubMed ID: 25412788
[TBL] [Abstract][Full Text] [Related]
5. Ten years on: the impact of biologics on the practice of dermatology.
Leonardi CL; Romiti R; Tebbey PW
Dermatol Clin; 2015 Jan; 33(1):111-25. PubMed ID: 25412787
[TBL] [Abstract][Full Text] [Related]
6. Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice.
Chalmers RJ
Dermatol Clin; 2015 Jan; 33(1):57-71. PubMed ID: 25412783
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis and the life cycle of persistent life effects.
Garshick MK; Kimball AB
Dermatol Clin; 2015 Jan; 33(1):25-39. PubMed ID: 25412781
[TBL] [Abstract][Full Text] [Related]
8. What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.
Talamonti M; Galluzzo M; Bianchi L; Boca AN; Costanzo A; Chimenti S
Dermatology; 2014; 229(4):324-32. PubMed ID: 25402662
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials.
Correr CJ; Rotta I; Teles Tde S; Godoy RR; Riveros BS; Garcia MM; Gonçalves PR; Otuki MF
Cad Saude Publica; 2013 Nov; 29 Suppl 1():S17-31. PubMed ID: 25402246
[TBL] [Abstract][Full Text] [Related]
10. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry.
Gisondi P; Cazzaniga S; Chimenti S; Maccarone M; Picardo M; Girolomoni G; Naldi L;
Br J Dermatol; 2015 Jun; 172(6):1613-1620. PubMed ID: 25401733
[TBL] [Abstract][Full Text] [Related]
11. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
13. IL-17 in psoriasis. The final frontier or just another brick in the wall?
Carrascosa JM; Puig L
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():6-8. PubMed ID: 25398487
[No Abstract] [Full Text] [Related]
14. Treatment satisfaction of patients with psoriasis.
Schaarschmidt ML; Kromer C; Herr R; Schmieder A; Goerdt S; Peitsch WK
Acta Derm Venereol; 2015 May; 95(5):572-8. PubMed ID: 25394584
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars in psoriasis 2015: what is next?
Puig L
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):467-9. PubMed ID: 25389042
[No Abstract] [Full Text] [Related]
16. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.
Sawyer LM; Wonderling D; Jackson K; Murphy R; Samarasekera EJ; Smith CH
Pharmacoeconomics; 2015 Feb; 33(2):163-77. PubMed ID: 25526841
[TBL] [Abstract][Full Text] [Related]
17. Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.
Spertino J; Lopez-Ferrer A; Vilarrasa E; Puig L
J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1514-21. PubMed ID: 25493314
[TBL] [Abstract][Full Text] [Related]
18. Effective management of psoriasis and psoriatic arthritis: insights on current and emerging therapies and enhanced professional collaboration.
Mease PJ; Armstrong AW
Semin Arthritis Rheum; 2014 Dec; 44(3):e7-8. PubMed ID: 25476667
[No Abstract] [Full Text] [Related]
19. Systematic review of cost-effectiveness analyses of treatments for psoriasis.
Zhang W; Islam N; Ma C; Anis AH
Pharmacoeconomics; 2015 Apr; 33(4):327-40. PubMed ID: 25475964
[TBL] [Abstract][Full Text] [Related]
20. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation.
Crowley JJ; Weinberg JM; Wu JJ; Robertson AD; Van Voorhees AS;
JAMA Dermatol; 2015 Jan; 151(1):87-94. PubMed ID: 25471223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
